Inducing iron deficiency improves erythropoiesis and photosensitivity in congenital erythropoietic porphyria

Blood

Volumn 126, Issue 2, 2015, Pages 257-261

  Egan, Daniel N ^a   Yang, Zhantao ^a   Phillips, John ^b   Abkowitz, Janis L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINOLEVULINATE SYNTHASE; DEFERASIROX; PORPHYRIN; BENZOIC ACID DERIVATIVE; IRON; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ARTICLE; BONE MARROW CELL; CASE REPORT; CONGENITAL ERYTHROPOIETIC PORPHYRIA; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ERYTHROPOIESIS; FEMALE; HUMAN; HUMAN CELL; IRON DEFICIENCY; OFF LABEL DRUG USE; PHOTOSENSITIVITY; PRIORITY JOURNAL; SYMPTOMATOLOGY; ADULT; ADVERSE EFFECTS; CELL CULTURE; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; FATALITY; GENETICS; INFANT; LIGHT; METABOLISM; PATHOLOGY; PORPHYRIA, ERYTHROPOIETIC; RADIATION TOLERANCE; SIBLING;

ADULT; BENZOATES; BONE MARROW CELLS; CELLS, CULTURED; ERYTHROPOIESIS; FATAL OUTCOME; FEMALE; HUMANS; INFANT; IRON; IRON CHELATING AGENTS; LIGHT; OFF-LABEL USE; PORPHYRIA, ERYTHROPOIETIC; RADIATION TOLERANCE; SIBLINGS; TRIAZOLES;

EID: 84937809925     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-584664     Document Type: Article

References (23)

1. Layer G, Reichelt J, Jahn D, Heinz DW. Structure and function of enzymes in heme biosynthesis. Protein Sci. 2010;19(6):1137-1161.
2. Thomas C, Ged C, Nordmann Y, et al. Correction of congenital erythropoietic porphyria by bone marrow transplantation. J Pediatr. 1996;129(3): 453-456.
3. Zix-Kieffer I, Langer B, Eyer D, et al. Successful cord blood stem cell transplantation for congenital erythropoietic porphyria (Gunther's disease). Bone Marrow Transplant. 1996;18(1):217-220.
4. Harada FA, Shwayder TA, Desnick RJ, Lim HW. Treatment of severe congenital erythropoietic porphyria by bone marrow transplantation. J Am Acad Dermatol. 2001;45(2):279-282.
5. Ged C, Moreau-Gaudry F, Richard E, Robert-Richard E, De Verneuil H. Congenital erythropoietic porphyria: Mutation update and correlations between genotype and phenotype. Cell Mol Biol (Noisy-le-grand). 2009;55(1):53-60.
6. Desnick RJ, Astrin KH. Congenital erythropoietic porphyria: Advances in pathogenesis and treatment. Br J Haematol. 2002;117(4):779-795.
7. Warner CA, Poh-Fitzpatrick MB, Zaider EF, Tsai SF, Desnick RJ. Congenital erythropoietic porphyria. A mild variant with low uroporphyrin I levels due to a missense mutation (A66V) encoding residual uroporphyrinogen III synthase activity. Arch Dermatol. 1992;128(9):1243-1248.
8. Xu W, Warner CA, Desnick RJ. Congenital erythropoietic porphyria: Identification and expression of 10 mutations in the uroporphyrinogen III synthase gene. J Clin Invest. 1995;95(2):905-912.
9. Solis C, Aizencang GI, Astrin KH, Bishop DF, Desnick RJ. Uroporphyrinogen III synthase erythroid promoter mutations in adjacent GATA1 and CP2 elements cause congenital erythropoietic porphyria. J Clin Invest. 2001; 107(6):753-762.
10. To-Figueras J, Ducamp S, Clayton J, et al. ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. Blood. 2011;118(6): 1443-1451.
11. Bhasker CR, Burgiel G, Neupert B, Emery-Goodman A, Kühn LC, May BK. The putative iron-responsive element in the human erythroid 5-aminolevulinate synthase mRNA mediates translational control. J Biol Chem. 1993;268(17): 12699-12705.
12. Melefors O, Goossen B, Johansson HE, Stripecke R, Gray NK, Hentze MW. Translational control of 5-aminolevulinate synthase mRNA by ironresponsive elements in erythroid cells. J Biol Chem. 1993;268(8):5974-5978.
13. Giarratana MC, Rouard H, Dumont A, et al. Proof of principle for transfusion of in vitro-generated red blood cells. Blood. 2011;118(19):5071-5079.
14. Freesemann AG, Gross U, Bensidhoum M, De Verneuil H, Doss MO. Immunological, enzymatic and biochemical studies of uroporphyrinogen IIIsynthase deficiency in 20 patients with congenital erythropoietic porphyria. Eur J Biochem. 1998; 257(1):149-153.
15. Piomelli S, Poh-Fitzpatrick MB, Seaman C, Skolnick LM, Berdon WE. Complete suppression of the symptoms of congenital erythropoietic porphyria by long-term treatment with high-level transfusions. N Engl J Med. 1986;314(16): 1029-1031.
16. Katugampola RP, Anstey AV, Finlay AY, et al. A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases. Br J Dermatol. 2012;167(4):888-900.
17. Tishler PV, Winston SH. Rapid improvement in the chemical pathology of congenital erythropoietic porphyria with treatment with superactivated charcoal. Methods Find Exp Clin Pharmacol. 1990;12(9):645-648.
18. Hift RJ, Meissner PN, Kirsch RE. The effect of oral activated charcoal on the course of congenital erythropoietic porphyria. Br J Dermatol. 1993; 129(1):14-17.
19. Minder EI, Schneider-Yin X, Möll F. Lack of effect of oral charcoal in congenital erythropoietic porphyria. N Engl J Med. 1994;330(15): 1092-1094.
20. Gorchein A, Guo R, Lim CK, Raimundo A, Pullon HW, Bellingham AJ. Porphyrins in urine, plasma, erythrocytes, bile and faeces in a case of congenital erythropoietic porphyria (Gunther's disease) treated with blood transfusion and iron chelation: Lack of benefit from oral charcoal. Biomed Chromatogr. 1998;12(6):350-356.
21. Fortian A, Gonź alez E, Castan?o D, Falcon-Perez JM, Millet O. Intracellular rescue of the uroporphyrinogen III synthase activity in enzymes carrying the hotspot mutation C73R. J Biol Chem. 2011;286(15):13127-13133.
22. Blouin J-M, Duchartre Y, Costet P, et al. Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria. Proc Natl Acad Sci USA. 2013;110(45):18238-18243.
23. Poh-Fitzpatrick MB, Piomelli S, Seaman C, Skolnick LM. Congenital erythropoietic porphyria: Complete suppression of symptoms by long-term high-level transfusion with deferoxamine infusion iron rescue. In: Orfanos CE, Stadler R, Gollnick H, eds. Dermatology in Five Continents. Berlin, Germany: Springer Verlag; 1988:876-879.